Linezolid: An oxazolidinone antimicrobial agent

Clinical therapeutics

Volumn 23, Issue 3, 2001, Pages 356-391

  Fung, Horatio B ^a   Kirschenbaum, Harold L ^b   Ojofeitimi, Babatunde O ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; LINEZOLID; OXAZOLIDINONE DERIVATIVE;

ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; CROSS INFECTION; DRUG INTERACTION; HUMAN; REVIEW; SOFT TISSUE INFECTION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG INTERACTIONS; HUMANS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; SOFT TISSUE INFECTIONS; VANCOMYCIN RESISTANCE;

EID: 0035293206     PISSN: 01492918     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80043-6     Document Type: Article

References (120)

1. RN Jones DE Low MA Pfaller Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: The role of streptogramins and other newer compounds Diagn Microbiol Infect Dis 33 1999 101 112
2. HS Fraimow E Abrutyn Pathogens resistant to antimicrobial agents—epidemiology, molecular mechanisms and clinical management Infect Dis Clin North Am 9 1995 497 530
3. RC Moellering Jr. A novel antimicrobial agent joins the battle against resistant bacteria Ann Intern Med 130 1999 155 157 Editorial
4. CW Ford JC Hamel DM Wilson In vitro activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections Antimicrob Agents Chemother 40 1996 1508 1513
5. SJ Brickner DK Hutchinson MR Barbachyn Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections J Med Chem 39 1996 673 679
6. JC Hamel D Stapert JK Moerman CW Ford Linezolid, critical characteristics Infection 28 2000 60 64
7. ™ 2000 Pharmacia & Upjohn Kalamzoo, Mich [package insert]
8. M Fines R Leclercq Activity of linezolid against gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors J Antimicrob Chemother 45 2000 797 802
9. P Kloss L Xiong DL Shinabarger AS Mankin Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center J Mol Biol 294 1999 93 101
10. SM Abdel-Rahman GL Kearns An update on the oxazolidinone antibiotics Pediatr Infect Dis J 18 1999 1101 1102
11. DL Shinabarger KR Marotti RW Murray Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions Antimicrob Agents Chemother 41 1997 2132 2136
12. H Bielka Properties and spatial arrangement of components in preinitiation complexes of eukaryotic protein synthesis Prog Nucleic Acid Res Mol Biol 32 1985 267 289
13. AH Lin RW Murray TJ Vidmar KR Marotti The oxazolidinone eperezolid binds to the 50 S ribosomal subunit and competes with binding of chloramphenicol and lincomycin Antimicrob Agents Chemother 41 1997 2127 2131
14. SM Swaney H Aoki MC Ganoza DL Shinabarger The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria Antimicrob Agents Chemother 42 1998 3251 3255
15. DJ Biedenbach RN Jones Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents J Clin Microbiol 35 1997 3198 3202
16. S Worth ME Erwin RN Jones Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials Diagn Microbiol Infect Dis 24 1996 87 91
17. RN Jones MA Pfaller ME Erwin ML Beach Antimicrobial activity of linezolid-tested against 7,599 recent clinical isolates from over 50 medical center laboratories. Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 1263
18. RN Jones MA Pfaller ME Erwin Antimicrobial activity of linezolid tested against 3808 strains of gram-positive organisms having resistances to various drugs Program and abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America 18211999 Philadelphia, Pa.
19. GA Noskin F Siddiqui V Stosor In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci Antimicrob Agents Chemother 43 1999 2059 2062
20. E Cercenado F Garcia-Garrote E Bouza In vitro activity of linezolid against multiple resistant gram-positive clinical isolates Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 1253
21. ML Mezzatesta S Stefani G Tempera Comparative activity of linezolid against staphylococci and enterococci isolated in Italy Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2302
22. GM Eliopoulos CB Wennersten HS Gold RC Moellering Jr. In vitro activities of new oxazolidinone antimicrobial agents against enterococci Antimicrob Agents Chemother 40 1996 1745 1747
23. ME Jones MR Visser M Klootwijk Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristindalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains Antimicrob Agents Chemother 43 1999 421 423
24. L Verbist J Verhaegen In vitro activity of linezolid against gram-positive cocci Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 24271998 San Diego, Calif. Abstract E-140
25. SK Spangler MR Jacobs PC Appelbaum Activities of RPR 106972, cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci Antimicrob Agents Chemother 40 1996 481 484
26. AP Borek LR Peterson GA Noskin Activity of linezolid against medically important gram-positive bacteria from 1997 to 1999 Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2299
27. C Betriu M Redondo A Boloix Comparative in vitro activities of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2294
28. JH Jorgensen ML McElmeel CW Trippy In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species Antimicrob Agents Chemother 41 1997 465 467
29. C Von Eiff G Peters Comparative in vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci J Antimicrob Chemother 43 1999 569 573
30. L Mulazimoglu SD Drenning VL Yu In vitro activities of two novel oxazolidinones (U-100592 and U-100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis Antimicrob Agents Chemother 40 1996 2428 2430
31. O Manzor J Pawlak L Saravolatz In vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae J Antimicrob Chemother 43 1999 31 36
32. MC Struwig PL Botha LJ Chalkley In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci Antimicrob Agents Chemother 42 1998 2752 2755
33. RN Jones DM Johnson ME Erwin In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones Antimicrob Agents Chemother 40 1996 720 726
34. R Patel MS Rouse KE Piper JM Steckelberg In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae Diagn Microbiol Infect Dis 34 1999 119 122
35. GE Zurenko BH Yagi RD Schaadt In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents Antimicrob Agents Chemother 40 1996 839 845
36. D Kato T Ito D Imai K Hiramatsu In vitro synergy between linezolid and sulbactam-ampicillin against methicillin-resistant Staphylococcus aureus clinical isolates including those with reduced susceptibility to vancomycin Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2297
37. M Wootton RA Howe TR Walsh In vitro activity of a range of old and new antimicrobials to hetero-vancomycin-intermediate Straphylococcus aureus Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2313
38. MJ Rybak E Hershberger T Moldovan RG Grucz In vitro activities of daptomycin, vancomycin, linezolid, and quinupristindalfopristin against staphylococci and enterococci including vancomycin-intermediate and -resistant strains Antimicrob Agents Chemother 44 2000 1062 1066
39. B Robinson-Dunn G Jennings J Mitchell Characterization of a unique isolate of vancomycin-intermediate Staphylococcus aureus Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 2811997 Toronto, Ont, Can. Abstract LB-14
40. C Betriu M Redondo ML Palau Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovalfloxacin against erythromycin-susceptible and -resistant streptococci Antimicrob Agents Chemother 44 2000 1838 1841
41. EO Mason Jr LB Lamberth SL Kaplan In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae Antimicrob Agents Chemother 40 1996 1039 1040
42. JCS Deazavedo L Trpeski S Pong-Porter Activity of linezolid on antibiotic-resistant and -susceptible strains of Streptococcus pneumoniae collected from across Canada Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 1255
43. GG Zhanel JA Karlowsky KA Nichol Linezolid is active against Streptococcus pneumoniae resistant to other protein synthesis inhibiting antibiotics Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2301
44. HM Wexler D Molitoris ML Vaisanen SM Finegold In vitro activity of linezolid, a new oxazolidinone against 127 anaerobes isolated from abdominal specimens and against 102 isolates (96 anaerobes) isolated from pulmonary specimens Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2304
45. EC Goldstein DM Citron CV Merriam Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans Antimicrob Agents Chemother 43 1999 1469 1474
46. F Marco M Almela J Nolla-Salas In vitro activities of 22 antimicrobial agents against Listeria monocytogenes strains isolated in Barcelona, Spain Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 523
47. KE Seward RN Master RS Jones In vitro activity of the new fluoroquinolones, impinenem-cilastatin, quinupristin-dalfopristin and linezolid, against 43 Aerococcus urinae isolates Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 2278
48. T Schulin CB Wennersten MJ Ferraro Susceptibility of Legionella spp to ketolide HMR 3647 and other newer antimicrobials Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 2811997 Toronto, Ont, Can. Abstract F-250
49. LL Dever AG Barbour In vitro activity of SCH 27899 and other antimicrobials against Borrelia spp Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 2811997 Toronto, Ont, Can. Abstract E-26
50. SA Salmon EL Portis CA Case Minimum inhibitory concentration determinations for oxazolidinone antimicrobial agents and comparator agents against strains of Rodococcus equi Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 24271998 San Diego, Calif. Abstract E-129
51. MC Di Pentima EO Mason Jr SL Kaplan In vitro antibiotic synergy against Flavobacterium meningosepticum: Implications for therapeutic options Clin Infect Dis 26 1998 1169 1176
52. M Wu P Aralor K Nash Linezolid, a new oxazolidinone, has activity in vitro and in macrophage culture system against Mycobacterium avium complex Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 24271998 San Diego, Calif. Abstract C-143
53. MH Cynamon SP Klemens CA Sharpe S Chase Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model Antimicrob Agents Chemother 43 1999 1189 1191
54. SM Swaney DL Shinabarger RD Schaadt Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23s rRNA Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 24271998 San Diego, Calif. Abstract C-104
55. GW Kaatz SM Seo In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis Antimicrob Agents Chemother 40 1996 799 801
56. ™ 2000 Pharmacia & Upjohn Kalamazoo, Mich [comprehensive review]
57. GE Zurenko WM Todd B Hafkin Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 848
58. P Linden D Parkinson AW Pasculle Isolation of a vancomycin-resistant enterococcal strain with reduced susceptibility to linezolid Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 1105
59. K Chiba KL Feenstra JG Slatter Absorption, distribution, metabolism and excretion of the oxazolidinone antibiotic linezolid in the Sprague-Dawley rat Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 24271998 San Diego, Calif. Abstract A-123
60. TL Sisson GL Jungbluth DJ Stalker NK Hopkins Effect of age and gender on the single-dose pharmacokinetics of linezolid Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 1194
61. TL Sisson GL Jungbluth NK Hopkins Effect of age and gender on linezolid pharmacokinetics Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones 26282000 Seville, Spain. Abstract 08-19
62. TL Sisson GL Jungbluth NK Hopkins A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam J Clin Pharmacol 39 1999 1277 1282
63. GL Jungbluth TL Sisson NK Hopkins Linezolid and aztreonam: A pharmacokinetic evaluation of intravenous coadministration in healthy volunteers Program and abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America 13161997 San Francisco, Calif.
64. GL Jungbluth TL Sisson NK Hopkins Linezolid and gentamicin: A pharmacokinetic evaluation of intravenous coadministration in healthy volunteers Program and abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America 13161997 San Francisco, Calif.
65. DJ Stalker CP Wajszczuk DH Batts Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 2811997 Toronto, Ont, Can. Abstract A-115
66. DJ Stalker CP Wajszczuk DH Batts Linezolid safety, tolerance and pharmacokinetics after intravenous dosing twice daily for 7.5 days Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 2811997 Toronto, Ont, Can. Abstract A-116
67. MA Wynalda MJ Hauer LC Wienkers Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes Drug Metab Dispos 28 2000 1014 1017
68. LC Wienkers MA Wynalda KL Feenstra In vitro metabolism of linezolid: Lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586 Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 11
69. KL Feenstra DJ Slatker Metabolism and excretion of the oxazolidinone antibiotic linezolid following oral administration of [14C]PNU-100766 to healthy human volunteers Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 24271998 San Diego, Calif. Abstract A-53
70. DJ Stalker GL Kearns L James Pharmacokinetics of linezolid in pediatric patients Program and abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America 12151998 Denver, Colo. Abstract 749
71. PE Hendershot GL Jungbluth SK Cammarata NK Hopkins Pharmacokinetics of linezolid in patients with liver disease Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones 26282000 Seville, Spain. Abstract 08-17
72. Center for Drug Evaluation and Research. Guidance for Industry—Pharmacokinetics in patients with impaired hepatic function: Study design, data analysis, and impact on dosing and labeling. Available at: http://www.fda.gov/cder/guidance/index/htm. Accessed December 10, 2000.
73. ME Brier DJ Stalker GR Aronoff Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones 26282000 Seville, Spain. Abstract 08-18
74. RD Schaadt DH Batts PT Daley-Yates Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid Diagn Microbiol Infect Dis 28 1997 201 204
75. GD Bostic MB Perri LA Thal MJ Zervos Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci Diagn Microbiol Infect Dis 30 1998 109 112
76. Denver, Colo. Abstract 54 LM Sciandra PG Pitsakis MH Chowdhury ME Levison In vitro activity of linezolid vs Staphylococcus aureus with and without rifampin Program and abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America 12151998
77. MJ Rybak DM Cappelletty T Moldovan Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus , coagulase-negative staphylococci, Enterococcus faecalis and Enterococcus faeciton Antimicrob Agents Chemother 42 1998 721 724
78. D Andes ML Van Ogtrop WA Craig Pharmacodynamic activity of a new oxazolidinone, linezolid, in an animal infection model Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones 26282000 Seville, Spain. Abstract 08–16
79. B Cirincione T Grasela S Sardella Population pharmacodynamic assessment of linezolid efficacy in community-acquired pneumonia, skin and soft tissue infections and bacteremia Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 1389
80. MT Sweeney KF Baldwin GE Zurenko In vitro activity of linezolid combined with other antibacterial agents Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 1252
81. MT Sweeney GE Zurenko In vitro activity of linezolid combined with numerous antibacterial agents Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2295
82. MC Birmingham GS Zimmer B Hafkin Outcomes with linezolid from an ongoing compassionate use trial of patients with significant resistant gram-positive infections Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 1098
83. MC Birmingham GS Zimmer B Hafkin Results of treating bacteremic patients with linezolid in a compassionate use trial for resistant gram-positive infections Program and abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America 18211999 Philadelphia, Pa.
84. PF Smith MC Birmingham GS Zimmer Clinical outcomes, safety and tolerance of linezolid for resistant gram-positive infections in patients with neutropenia Program and abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America 18211999 Philadelphia, Pa.
85. TS Leach R Schaser K Hempsall Clinical efficacy of linezolid for infections caused by vancomycin-resistant enterococci in a compassionate use program Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America 7102000 New Orleans, La. Abstract 66
86. PA Moise MC Birmingham A Forrest JJ Schentag Linezolid use in patients who are intolerant to or fail vancomycin Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2233
87. MC Birmingham CR Rayner SM Flavin Treating outpatients with significant resistant gram-positive infections with linezolid Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America 7102000 New Orleans, La. Abstract 61
88. JW Chien ML Kucia RA Salata Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections Clin Infect Dis 30 2000 146 151
89. PA Grossi DD Gasperina L Perversi Compassionate linezolid treatment of severe methicillin-resistant Staphylococcus aureus tracheo-bronchitis following lung transplantation Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2232
90. TS Leach RW Kaja S Eckert Linezolid versus vancomycin for the treatment of MRSA infections: Results of a randomized phase III trial Program and abstracts of the 9th International Congress on Infectious Disease 10132000 Buenos Aires, Argentina
91. M Melzer D Goldsmith W Gransden Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias Clin Infect Dis 31 2000 208 209
92. SJ Antony KM Bitter T Moreland Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): New treatment options for infections due to resistant organisms Clin Infect Dis 29 1999 1341 1342
93. CS Hartman TS Leach RW Kaja Linezolid in the treatment of vancomycin-resistant enterococcus: A dose comparative, multicenter phase III trial Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2235
94. TS Leach RJ Schaser WM Todd Efficacy of linezolid in patients infected with vancomycin-resistant enterococcus based on severity of illness Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America 7102000 New Orleans, La. Abstract 62
95. S Lemeshow D Teres J Klar Mortality Probability Models (MPM II) based on an international cohort of intensive care unit patients JAMA 270 1993 2478 2486
96. TS Leach RJ Schaser WM Todd Linezolid in the treatment of intra-abdominal infections caused by vancomycin-resistant enterococcus Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America 7102000 New Orleans, La. Abstract 63
97. GA Noskin F Siddiqui V Stosor LR Peterson Linezolid for the treatment of vancomycin-resistant enterococci in immunocompromised hosts Program and abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America 18211999 Philadelphia, Pa.
98. GA Noskin F Siddiqui V Stosor Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin Clin Infect Dis 28 1999 689 690
99. SA McNeil NM Clark PH Chandrasekar CA Kauffman Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin) Clin Infect Dis 30 2000 403 404
100. H Polenakovik C Bacheller J Bernstein Vancomycin-resistant Enterococcus faecium meningitis in a patient with underlying strongloidiasis treated with linezolid Program and abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America 18211999 Philadelphia, Pa.
101. SK Cammarata JA Timm KA Hempsall Linezolid is equivalent to vancomycin in the treatment of patients with gram-positive nosocomial pneumonia Program and abstracts of the 96th International Conference of the American Thoracic Society 5102000 Toronto, Ont, Can.
102. WA Knaus EA Draper DP Wagner JE Zimmerman APACHE II: A severity of disease classification system Crit Care Med 13 1985 818 829
103. SK Cammarata RG Wunderink KA Hempsall Efficacy of linezolid in patients with nosocomial pneumonia based on severity of illness as determined by baseline APACHE II score Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2234
104. SK Cammarata H Standiford TH Oliphant B Hafkin Prospective surveillance for appearance of vancomycin-resistant enterococci in stool during a comparison trial of vancomycin versus linezolid in nosocomial pneumonia Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 1961
105. SK Cammarata B Hafkin WM Todd DH Batts Efficacy of linezolid in community-acquired S pneumoniae pneumonia Program and abstracts of the 95th International Conference of the American Thoracic Society 23281999 San Diego, Calif.
106. JB Bruss C Seas SE Duvall Comparison of linezolid to oxacillin followed by oral dicloxacillin in the treatment of complicated skin infections: Results from a multinational phase III trial Program and abstracts of the 9th International Congress on Infectious Disease 10132000 Buenos Aires, Argentina
107. TS Leach RJ Schaser WM Todd Clinical efficacy of linezolid for complicated skin and soft tissue infections caused by MRSA Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America 7102000 New Orleans, La. Abstract 60
108. LD Dresser MC Birmingham AW Karchmer Results of treating infective endocarditis with linezolid Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2239
109. DT Durack AS Lukes DK Bright New criteria for diagnosis of infective endocarditis: Utilization of echocardiographic findings Am J Med 96 1994 200 209
110. JS Li DJ Sexton N Mick Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis Clin Infect Dis 30 2000 633 638
111. JB Bruss LG Smith SE Duvall Safety and tolerance of linezolid: Adverse events reported in phase III trials Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2236
112. NE Wilks Safety and tolerance of linezolid in phase II trials Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 26291999 San Francisco, Calif. Abstract 1763
113. SK Cammarata V Le TH Oliphant Incidence of Clostridium difficile —related complications during clinical trials of linezolid, an oxazolidinone Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 947
114. JP Martin JT Herberg JG Slatter MJ Dupuis Although a novel microtiter-plate assay demonstrates that linezolid is a weak competitive inhibitor of human monoamine oxidase, no clinical evidence of MAO A inhibition in clinical trials has been observed Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 24271998 San Diego, Calif. Abstract A-85
115. TS Leach FG Lobeck WM Todd B Hafkin Lack of serotonin syndrome in phase III patients receiving linezolid and a selective serotonin reuptake inhibitor Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America 7102000 New Orleans, La. Abstract 64
116. LA Trissel KY Williams DL Gilbert Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions J Am Pharm Assoc 40 2000 515 519
117. QA Xu LA Trissel KY Williams Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics J Am Pharm Assoc 40 2000 509 514
118. Y Zhang QA Xu LA Trissel KY Williams Compatibility and stability of linezolid injection admixed with three quinolone antibiotics Ann Pharmacother 34 2000 996 1001
119. BE Rittenhouse Z Li RJ Willke Re-examining hospital length of stay reduction potential in a randomized multicenter clinical trial of methicillin-resistant staphylococci species: Linezolid vs vancomycin Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 2132
120. RJ Willke ZJ Li BE Rittenhouse Linezolid's effects on early hospital discharge in hospitalized patients with complicated skin and soft tissue infections under varying rates of methicillin-resistant Staphylococcus infection: Analysis of results from two randomized clinical trials Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 17202000 Toronto, Ont, Can. Abstract 112